Oxazolidone derivatives as PR modulators

Details Oxazolidone derivatives as PR modulators Oxazolidone derivatives as PR modulators

2007-08-13

2009-11-17

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S190000

Reexamination Certificate

active

07618990

ABSTRACT:
Compounds of the following structure are described:wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

REFERENCES:
patent: 3474462 (1969-10-01), Breuer
patent: 4008243 (1977-02-01), Wikel et al.
patent: 4150028 (1979-04-01), Paget et al.
patent: 4216313 (1980-08-01), Paget et al.
patent: 4268679 (1981-05-01), Lavanish
patent: 4293558 (1981-10-01), Paget et al.
patent: 4426527 (1984-01-01), Lavanish et al.
patent: 4756744 (1988-07-01), Schwindemann
patent: 5714607 (1998-02-01), Padmanathan
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5827857 (1998-10-01), Riedl
patent: 5972372 (1999-10-01), Saleh et al.
patent: 6125850 (2000-10-01), Sokal et al.
patent: 6126958 (2000-10-01), Saleh
patent: 6239152 (2001-05-01), Gordeev et al.
patent: 6436966 (2002-08-01), Ohkawa et al.
patent: 6531470 (2003-03-01), Gordeev et al.
patent: 2002/0115669 (2002-08-01), Wiedeman et al.
patent: 2002/0183371 (2002-12-01), Gordeev et al.
patent: 2003/0114491 (2003-06-01), Kim et al.
patent: 2004/0157883 (2004-08-01), Chen et al.
patent: 2004/0167192 (2004-08-01), Solow-Cordero et al.
patent: 2004/0214870 (2004-10-01), Xin et al.
patent: 32 27 329 (1984-01-01), None
patent: 196 04 223 (1997-08-01), None
patent: 196 49 095 (1997-08-01), None
patent: 100 34 622 (2002-01-01), None
patent: 100 34 623 (2002-01-01), None
patent: 100 34 628 (2002-01-01), None
patent: 0 300 272 (1992-09-01), None
patent: 0 693 491 (1996-01-01), None
patent: 0 770 613 (1996-10-01), None
patent: 0 789 026 (1997-08-01), None
patent: 0 894 497 (1998-07-01), None
patent: 0 789 025 (2001-04-01), None
patent: 1224995 (1971-03-01), None
patent: 6703864 (1967-03-01), None
patent: 6706448 (1967-05-01), None
patent: WO 92/07567 (1992-05-01), None
patent: WO 92/09586 (1992-06-01), None
patent: 7-149745 (1995-06-01), None
patent: WO 95/15955 (1995-06-01), None
patent: WO 98/04534 (1998-02-01), None
patent: WO 99/42455 (1999-08-01), None
patent: WO 01/70733 (2001-09-01), None
patent: WO 01/74811 (2001-10-01), None
patent: WO 02/081453 (2002-10-01), None
patent: WO 03/011859 (2003-02-01), None
patent: WO 03/101985 (2003-12-01), None
patent: WO 2004/014899 (2004-02-01), None
patent: WO 2004/019938 (2004-03-01), None
patent: WO 2004/087698 (2004-10-01), None
patent: WO 2004/089303 (2004-10-01), None
patent: WO 2005/005435 (2005-01-01), None
Wolff et al., Burger's Medicinal Chemistry and Drug Discovery, 1994, Wiley-lnterscience, Fifth Edition, vol. I: Principles and Practice, pp. 975-977.
Metabolomics [online], Retrieved from the Internet Jun. 16, 2008, www.en.wikipedia.org/wiki/Metabolomics.
Kwon et al., Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists, 2001, http://www.myilibrary.com/Browse/open.asp?ID=4284&loc=1, Retrieved from the Internet Jun. 16, 2008, p. 213.
U.S. Appl. No. 11/891,729, filed Aug. 13, 2007, Commons et al.
U.S. Appl. No. 11/891,727, filed Aug. 13, 2007, Commons et al.
U.S. Appl. No. 11/891,821, filed Aug. 13, 2007, Commons et al.
U.S. Appl. No. 11/891,728, filed Aug. 13, 2007, Commons et al.
U.S. Appl. No. 11/891,747, filed Aug. 13, 2007, Commons et al.
David J. Mangelsdorf, Carl Thummel, Miguel Beato, Peter Herrlich, Günther Schütz, Kazuhiko Umesono, Bruce Blumberg, Philippe Kastner, Manuel Mark, Pierre Chambon and Ronald M. Evans, The nuclear receptor superfamily: The second decade, Cell, vol. 83, Issue 6, Dec. 15, 1995, pp. 835-839.
André Ulmann, Rémi Peyron and Louise Silvestre, Clinical Uses of Mifepristone (MFP), Annals of the New York Academy of Sciences, Jun. 1995—vol. 761 Steroid Receptors and Antihormones, pp. 248-260.
Kekkonen, et al, Fertility and Sterility, 60, 610, 1993.
Horwitz, et al, Horm. Cancer, 283, 1996, pub: Birkhaeuser, Boston, Mass., ed. Vedeckis.
AA Murphy, LM Kettel, AJ Morales, VJ Roberts, and SS Yen, Regression of uterine leiomyomata in response to the antiprogesterone RU 486, J Clin Endocrinol Metab 1993 76: 513-517.
Kettel, et al., Fertility and Sterility, 56, 402, 1991.
Horst Michna, Karsten Parczyk, Martin R. Schneider and Yukishige Nishino, Differentiation Therapy with Progesterone Antagonists Annals of the New York Academy of Sciences, Jun. 1995—vol. 761 Steroid Receptors and Antihormones, pp. 224-247.
B. Testa and J. Caldwell, “Prodrugs Revisited: The “Ad Hoc” Approach as a Complement to Ligand Design”, Medicinal Research Reviews, 16(3):233-241, ed., John Wiley & Sons (1996).
Lautens, M.; Roy, A.: Synthetic Studies of the Formulation of Oxazoles and lsoxazoles from N-Acetoacetyl Derivatives Organic Letters, vol. 2, No. 4, 2000, pp. 555-557.
Collins et al., Novel pyrrole-containing progesterone receptor modulators, Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, pp. 2185-2189.

Affiliated with

Also associated with

Rating

Oxazolidone derivatives as PR modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxazolidone derivatives as PR modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazolidone derivatives as PR modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4094215